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ABSTRACT 
Tibolone,  which  is  indicated  for  the  relief  of  climacteric  symptoms  and  the  prevention  of 
osteoporosis in postmenopausal women, has a tissue-speciﬁc mode of action different to that of 
conventional hormone replacement therapy (HRT). A large proportion of Asian postmenopausal 
women  experience  symptoms  that  most  frequently  include  musculoskeletal  pain,  insomnia, 
forgetfulness, hot ﬂushes and sexual dysfunction, and there is a need to address their speciﬁc 
requirements.  Recent  studies  show  that,  in  comparison  to  HRT,  tibolone  is  as  effective  in 
alleviating menopausal symptoms and preventing bone loss, has a greater positive effect on sexual 
dysfunction and is associated with less vaginal bleeding, but it is rarely mentioned in guidelines for 
menopausal treatment. Levels of awareness amongst women about treatments for menopausal 
symptoms vary between Asian countries but, even in countries where awareness is high, HRT 
usage is much lower than in the West. To provide a practical approach to the use of tibolone in 
Asian postmenopausal women, a panel of experts in the management of menopause from 11 Asia 
Paciﬁc countries has developed recommendations for its use, based on the evidence from clinical 
studies  published  since  2005.  However,  as  much  of  the  clinical  data  reviewed  are  from 
international studies, the recommendations and the treatment algorithm presented here are widely 
applicable. 
INTRODUCTION 
Tibolone  is  indicated  for  the  relief  of  climacteric  conversion of endogenous estrone sulfate to the active 
symptoms  and  the  prevention  of  osteoporosis  in  hormones estrone and 17b-estradiol
2. 
postmenopausal women. It is described as a selective  Tibolone  and  conventional  hormone  replacement 
tissue estrogenic activity regulator (STEAR) because it  therapy (HRT, either estrogen therapy (ET) or estro 
has speciﬁc effects in different tissues after conversion to  gen–progestogen  therapy  (EPT))  are  considered  to 
three  active  metabolites  following  oral  ingestion
1.  offer  equivalent  relief  of  vasomotor  symptoms  of 
Estrogenic metabolites act centrally, on bone and the  menopause
3–5, but there is evidence that tibolone results 
vagina,  and,  together  with  androgenic  metabolites,  in  better  female  sexual  function
6–8,  particularly  with 
relieve  hot  ﬂushes  and  improve  energy  and  sexual  respect  to  desire  and  arousal
9,  probably  due  to  its 
well-being.  The  progestogenic  D4-isomer  of  tibolone  combined  estrogenic  and  androgenic  properties.  Im 
prevents stimulation of the endometrium, while breast  provements on psychological and somatic scales have 
tissue  stimulation  is  minimized  due  to  the  effects  also been found to be superior with tibolone compared 
of  tibolone  on  local  enzyme  activity,  which  inhibit  with  traditional  HRT
10.  Tibolone  is  well  tolerated
11 
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and  does  not  cause  weight  gain  in  menopausal 
12 
trium
women  .  Tibolone  does  not  stimulate  the  endome-
13,14, and, in comparison to EPT, does not increase 
the size of uterine myomas
15. The Long-term Interven 
tion on Fractures with Tibolone (LIFT) study showed 
that  tibolone  reduces  the  risk  of  vertebral  fractures 
and  possibly  colon  cancer,  but  increased  the  risk  of 
stroke in older women with osteoporosis
16. Tibolone 
does  not  increase  mammographic  density
17  and,  in 
the  LIFT  study  in  older  women  with  no  previous 
history,  tibolone  reduced  the  risk  of  breast  cancer
16. 
However,  the  Livial
1  Intervention  Following  Breast 
Cancer;  Efﬁcacy,  Recurrence  and  Tolerability  End 
points (LIBERATE) trial showed an increased risk of 
recurrence of breast cancer with tibolone
18, and hence it 
is  contraindicated  in  women  with  known,  past  or 
suspected breast cancer. 
RATIONALE  FOR  UPDATED 
RECOMMENDATIONS  FOR  TIBOLONE 
It was once assumed that the menopause was an event 
whose  timing  and  physiological  implications  were 
universally  the  same.  However,  both  biological  and 
cultural variables can inﬂuence symptomatology. Age, 
symptoms  and  mortality  can  vary  tremendously  be 
tween different parts of the world, even within countries 
in  Asia  Paciﬁc
19,20  (discussed  further  below).  Discre 
pancies between physicians’ perceptions and women’s 
reports  about  the  reasons  for  which  they  consult 
physicians at menopause are also seen, and prescription 
patterns and perceived beneﬁts of HRT can reﬂect local 
medical culture. 
The value of addressing region-speciﬁc elements of 
menopause care and decision-making has been recog 
nized  by  the  Asia  Paciﬁc  Menopause  Federation 
(APMF) and their 2008 consensus statement highlights 
the  essential  nature  of  individualized  management
21. 
Because  tibolone  has  a  different  pharmacological 
proﬁle to conventional HRT, separate guidelines that 
provide a practical tool for everyday use by gynecol 
ogists and general practitioners are of value. However, 
there  is  no  mention  of  tibolone  in  the  European 
Menopause  and  Andropause  Society  (EMAS)  2004/ 
2005 position statements on peri- and postmenopausal 
HRT
22,  the  2007  International  Menopause  Society 
(IMS)  updated  recommendations  on  postmenopausal 
hormone therapy
23, or the 2008 position statement of 
the North American Menopause Society
24. Guidelines 
generated at the fourth Amsterdam Menopause Sym 
posium  in  2004
22  stated  only  that  ‘Tibolone  is  as 
effective  as  hormone  therapy  (HT)  in  treating  symp 
toms  and  preventing  bone  loss,  and  it  improves 
sexuality’. Although Kenemans and colleagues
25  pub 
lished  an  excellent  summary  of  the  evidence-based 
consensus  ﬁndings  for  the  use  of  tibolone  in  2005, 
that paper did not contain detailed practical guidelines 
for  its  use  and  several  large,  randomized  trials  have 
since yielded additional data on tibolone’s efﬁcacy and 
safety proﬁle. 
A  panel  of  experts  in  the  management  of  the 
menopause from 11 Asia Paciﬁc countries (Australia, 
China, India,  Indonesia,  Korea,  Malaysia,  the  Philip 
pines,  Singapore,  Taiwan,  Thailand  and  Vietnam) 
therefore met in Siem Reap, Cambodia, in June 2009 
to develop recommendations for the use of tibolone to 
treat  climacteric  symptoms  in  postmenopausal  Asian 
women. 
EXPERIENCE  OF  MENOPAUSE  IN  ASIAN 
WOMEN 
Numerous reviews and studies show that the relative 
prevalence  of  postmenopausal  symptoms  in  Asian 
women can differ substantially from those in Western 
women  and  between  (and  even  within)  Asian  coun-
tries
26–30  . 
tries
Whereas  vasomotor  symptoms  such  as  hot  ﬂushes 
and  night  sweats  are  generally  the  most  commonly 
reported  menopausal  symptoms  in  Western  coun-
20,31,  this  is  not  always  the  case  in  many  Asian 
countries.  In  a  2006  survey  of  over  1000  Asian 
20  women  , the most common reason for seeking treat 
ment  was  insomnia  (reported  by  42%).  Hot  ﬂushes 
were  reported  by  37%  of  the  Asians  who  sought 
treatment, compared to 59% of Europeans in a separate 
32  survey  . In the Pan Asian Menopause (PAM) study of 
1028  Asian  women  from  nine  ethnic  groups
27,  the 
prevalence  of  vasomotor  symptoms  ranged  from  5% 
in Indonesian women to 100% in Vietnamese women. 
The  prevalence  of  vasomotor  symptoms  also  varies 
within  countries:  a  study  of  menopausal  symptoms 
in  Chinese  women  showed  a  signiﬁcantly  lower  pre 
valence  among  rural  farming  women  (28%)  than 
among  urban  women  (47%)
29,  and  the  prevalence 
of  hot  ﬂushes  varied  from  25%  to  80%  in  Thai 
postmenopausal  women  in  three  different  studies
31. 
Amongst Australian postmenopausal women, the pre 
valence of vasomotor symptoms ranged from 45% to 
80% over ﬁve studies
31. 
In the PAM study, body or joint aches were the most 
commonly reported symptoms (by 88% overall – the 
range  was  from  76%  in  Korean  women  to  96%  in 
Vietnamese women)
27. Bone or joint pain was also the 
most prevalent currently experienced symptom (by 38% 
of  participants)  in  a  Korean  study  of  1201  Korean 
menopausal  and  postmenopausal  women
30,  followed 
by forgetfulness (35%). Forgetfulness was the second 
most  common  symptom  experienced  overall  in  that 
study (by 48%) and in the PAM study (by 81%). Other 
commonly reported symptoms (by over 45% of post 
menopausal  women  in  different  Asian  countries) 
include  insomnia,  headache,  irritability  and  palpita-
tions
19,27,28,30  . 
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Vaginal dryness or irritation was reported by 55% of 
women in the PAM study and dyspareunia by 30%
27. 
The prevalence of dyspareunia was 44% in a Malaysian 
study of postmenopausal women
33, 32% in a Taiwa 
nese study
28 and ranged from 7.7% in Singaporeans to 
46.9%  of  Indonesians  in  a  study  of  menopausal 
symptoms across seven Asian countries
19. 
REVIEW  OF  MOST  RECENT  DATA 
FROM  INTERNATIONAL  STUDIES  OF 
TIBOLONE 
Since the 2005 publication of consensus recommenda 
tions  for  the  use  of  tibolone  as  postmenopausal 
therapy
25, data from seven large, randomized, clinical 
trials of tibolone have been published and are summar 
ized  in  the  Appendix.  These  studies  conﬁrmed  that 
tibolone is signiﬁcantly more effective than placebo
18 
and  as  effective  as  low-dose  continuous  combined 
estradiol  plus  norethisterone  acetate  (E2/NETA)
34  in 
reducing vasomotor symptoms. 
Tibolone  was  associated  with  signiﬁcantly  greater 
improvements in sexual interest than transdermal E2/ 
NETA, and showed a trend towards greater improve 
ment  in  sexual  function
8.  Incidences  of  both  vaginal 
bleeding and breast tenderness/pain were signiﬁcantly 
lower with tibolone than with either oral or transdermal 
E2/NETA
8,34  or  continuous  combined  conjugated 
equine  estrogen  plus  medroxyprogesterone  acetate 
(CEE/MPA)
35.  Data  from  the  Tibolone  Histology  of 
the  Endometrium  and  Breast  Endpoints  Study 
(THEBES) conﬁrmed the endometrial safety of tibolone 
over 2 years at doses of both 1.25 mg and 2.5 mg per 
day with no cases of endometrial hyperplasia or cancer 
in either dosage group
35. 
Tibolone  (1.25  and  2.5 mg,  respectively)  increased 
lumbar and hip bone mineral density to a signiﬁcantly 
greater  extent  than  placebo  in  women  with
16  and 
without osteoporosis
18, as did a dose of 1.25 mg/day 
compared with raloxifene in a study of older osteopenic 
women  (mean  age  66  years)
36.  The  lower  dose  also 
reduced the risk of vertebral and non-vertebral fractures 
in older osteoporotic women (mean age 68.3 years) in 
the LIFT study
16. 
A greater risk of stroke, which increased further with 
age, was observed with tibolone than with placebo in 
the LIFT study
16. However, the differences in absolute 
risk  between  treatment  groups  were  not  statistically 
signiﬁcant,  the  study  population  was  elderly  (60–85 
years)  and  no  increase  in  the  risk  of  venous  throm 
boembolism was seen. By contrast, no increased risk of 
stroke was observed in the THEBES study (mean age 
54.4 years) or in a case–control study of women aged 
50–79 years (mean 70.3 years)
37, although the number 
of  tibolone-treated  cases  in  the  latter  study  was 
small. The LIFT investigators concluded that tibolone 
should  not  be  used  in  elderly  women  (i.e.  over  60 
years) or those who have strong risk factors for stroke, 
such  as  hypertension,  smoking,  diabetes  and  atrial 
ﬁbrillation
16. 
In the Osteoporosis Prevention and Arterial effects of 
tiboLone  (OPAL)  study,  which  was  designed  to 
compare  the  risk  of  cardiovascular  disease  between 
tibolone, CEE/MPA and placebo, tibolone reduced total 
cholesterol and high density lipoprotein (HDL) choles 
terol to a greater extent than placebo, whereas CEE/ 
MPA increased HDL cholesterol
38. The mean increase 
in  carotid  intima-media  thickness  (CIMT),  which  is 
related  to  risk  of  cardiovascular  disease,  was  similar 
with  tibolone  and  CEE/MPA  and  greater  than  with 
placebo. However, inconsistencies in the CIMT ﬁndings 
were observed between the European and US cohorts in 
this  study
39.  It  was  concluded  that  neither  treatment 
showed either beneﬁcial or harmful effects with regard 
to atherosclerosis
38,39. No increased risk of myocardial 
infarction was found with tibolone in a 5-year national 
cohort study in Denmark
40. 
In the LIFT study, compared with placebo, tibolone 
was associated with a reduced risk of breast cancer in 
older  women  with  no  prior  history  of  the  disease
16. 
Observational  studies  have  provided  conﬂicting  ﬁnd 
ings  on  this  issue:  a  large  UK  case–control  study 
showed no increase in breast cancer risk
41, while the 
Million Women Study showed an increased risk with 
tibolone
42.  The  LIBERATE  trial  was  conducted  to 
determine  whether  tibolone  could  be  prescribed  to 
women  with  a  previous  history  of  breast  cancer  to 
alleviate their menopausal symptoms without increas 
ing  their  risk  of  recurrence.  However,  this  study 
showed  a  signiﬁcantly  greater  risk  of  breast  cancer 
recurrence  in the tibolone group than in the placebo 
group, despite the fact that the majority of the study 
population  was  receiving  adjuvant  systemic  therapy. 
At  study  entry,  66%  of  the  study  populations  were 
receiving tamoxifen and 6% aromatase inhibitors. Use 
of aromatase inhibitors increased during the trial and, 
at  the  study  close,  approximately  80%  were  on 
adjuvant  endocrine  therapy
18.  Subgroup  analyses 
suggested that the interference of tibolone in users of 
aromatase inhibitors was more severe than in tamox 
ifen  users,  where  the  activation  of  the  estrogen 
receptor  by  the  estrogenic  metabolites  of  tibolone  is 
prevented  by  high-afﬁnity  hydroxyl-tamoxifen  mole 
cules. The investigators concluded that the discrepan 
cies between these ﬁndings and those of the LIFT study 
arose  because  the  two  study  populations  differed  in 
many  respects,  including  hormonal  risk  factors  for 
breast cancer, and because the effects of tibolone on 
healthy breast tissue most probably differ from those 
on  cancer  cells  as  tibolone  may  exert  an  estrogenic 
effect on occult, dormant breast cancer metastasis. On 
the basis of data from the LIBERATE trial, tibolone is 
contraindicated  for  women  with  known,  past  or 
suspected breast cancer. 
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CLINICAL  EXPERIENCE  OF  TIBOLONE 
IN  ASIAN  WOMEN 
Several  randomized  clinical  studies  of  tibolone  in 
Asian populations have been published, and, although 
these are small (generally fewer than 100 participants), 
the  ﬁndings  are  consistent  with  those  of  the  larger 
international  trials  described  previously.  A  6-month 
study  of  tibolone  (2.5 mg/day)  versus  CEE/MPA 
(0.625/5 mg/day)  in  Taiwanese  women  showed  that 
both  treatments  preserved  cognitive  function  as 
assessed  by  the  Cognitive  Abilities  Screening  Instru 
ment  and  the  Mini  Mental  State  Examination
43.I n 
another  Taiwanese  study  of  similar  design,  tibolone 
resulted in signiﬁcantly  higher scores than CEE/MPA 
for all aspects of sexuality, as assessed by the McCoy 
sex  scale,  including  vaginal  dryness  and  painful 
intercourse
44.  A  third  Taiwanese  study  showed  a 
signiﬁcant  increase  in  lumbar  bone  mineral  density 
with  tibolone  (but  not  CEE/MPA)  and  that  tibolone 
alleviated  climacteric  complaints  (as  assessed  using 
the  Greene  Climacteric  Scale  (GCS))  more  quickly 
and effectively than CEE/MPA
45. In all three studies, 
no  changes  in  endometrial  thickness  were  observed 
with  either  treatment,  and  tibolone  use  was  associa 
ted  with  a  substantially  lower  incidence  of  vaginal 
bleeding  compared  with  CEE/MPA.  A  Hong  Kong 
study  of  the  same  design  also  showed  a  signiﬁcantly 
beneﬁcial  effect  with  tibolone  on  GCS  somatic  sub 
46  scores  . 
Reduced levels of total cholesterol, triglycerides and 
HDL cholesterol were seen with tibolone in the third 
Taiwanese  study,  although  low  density  lipoprotein 
(LDL)  cholesterol  levels  increased  slightly.  Similar 
ﬁndings were reported in a Korean study
47, although, 
in  the  latter,  LDL  cholesterol  levels  were  slightly 
reduced with tibolone. In the Korean study, tibolone 
also  signiﬁcantly  improved  ﬂow-mediated  brachial 
artery  dilator  response  to  the  same  extent  as  CEE/ 
MPA, but did not signiﬁcantly change high-sensitivity 
Table  1  Consensus statements on the use of tibolone and levels of supporting evidence 
Updated  statements  and/or  new  evidence  published  since  2005  Level  of  evidence* 
Tibolone is as effective as currently used EPT/ET regimens in the management  1b 
of climacteric symptoms
34 
Tibolone treats vaginal atrophy and alleviates local vaginal symptoms
34  1b 
Tibolone has a positive effect on sexual well-being and is more effective than  1b 
oral EPT/ET in some respects, namely arousal, desire, and satisfaction
8,34 
Tibolone positively affects mood and quality of life
8,34  1b 
Tibolone prevents bone loss and is as effective as standard doses of EPT/ET and  1b 
more effective than raloxifene 
36 
Tibolone reduces the risk of vertebral and non-vertebral fracture in older osteoporotic  1b 
women. The absolute reduction was greater among women who had already had a 
vertebral fracture than among those who had not
16 
Tibolone does not stimulate the endometrium or induce endometrial hyperplasia or  1b 
carcinoma in postmenopausal women in randomized controlled clinical trials and 
has a low incidence of bleeding
34,35,61 
In observational studies, an increased relative risk of endometrial cancer has been shown
56,57  3b 
Tibolone causes less breast tenderness and less mastalgia than EPT
34  1b 
Tibolone does not increase mammographic density  2b 
Tibolone, taken by women with a personal history of breast cancer, is associated with  1b 
an increased risk of recurrence 
18 
The evidence of tibolone use and increased risk of breast cancer from observational studies  3b 
remains inconclusive
41 
Tibolone 1.25 mg does not increase breast cancer risk in older osteoporotic women with no  1b 
history of breast cancer 
16 
There are still no hard endpoint data on the effect of tibolone on cardiovascular health
38  1b 
Tibolone has different effects on lipids compared with EPT/ET
38  1b 
Tibolone increases CIMT in a manner similar to EPT
38  1b 
In one randomized, controlled trial, use of tibolone 1.25 mg in older women was associated with  1b 
an increased risk of stroke
16. Hence, tibolone should be used with caution in elderly women 
(i.e. over 60 years) and should not be used in those who have strong risk factors for stroke 
Tibolone did not increase the risk of stroke, VTE or myocardial infarction in observational studies
37,40  2b 
*Deﬁnitions of levels of evidence: 1b, individual randomized trials; 2b, individual cohort study; 3b, individual case–control study
55 
EPT, estrogen–progestogen therapy; ET, estrogen therapy; CIMT, carotid intima-media thickness; VTE, venous thromboembolism 
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C-reactive  protein  or  antithrombin  III  levels.  The 
investigators  concluded  that,  overall,  tibolone  has 
complex effects on lipids, some that might be expected 
to improve the cardiovascular risk proﬁle  and others 
that might worsen it. 
women
The ﬁndings of increased risk of stroke with tibolone 
in the LIFT study may not have as strong implications 
for Asian women as for Western women. The incidence 
of  stroke  is  generally  lower  in  Asian  than  Western 
48,49, and obesity and thrombophilia, two of the 
largest risk factors, tend to be less prevalent in Asian 
populations
50. 
The  breast  tissue  of  Asian  women  tends  to  show 
greater  mammographic  density  than  that  of  Western 
51,52  women  ,  which  can  impair  the  interpretation  of 
mammograms.  HRT  has  been  shown  to  cause  an 
increase  in  mammographic  density
17,53,  but  tibolone 
has been shown to either decrease
53 or have no effect 
on mammographic density
17,54. Hence, tibolone treat 
ment  may  be  preferable  to  HRT  in  symptomatic 
menopausal  women  with  mammographically  dense 
breast tissue. 
RECOMMENDATIONS  FOR  TIBOLONE 
USE 
Based on the evidence described here, the expert panel 
developed  the  consensus  statements  for  the  use  of 
tibolone  that  are  shown  in  Table  1.  The  levels  of 
evidence  for  each  statement  were  assigned  using  the 
criteria established by the Oxford Centre for Evidence-
based Medicine
55. 
The panel agreed that there was a need for data on 
the  possible  effects  of  tibolone  on  musculoskeletal 
symptoms, given their frequency in Asian women, as 
well  as  for  more  long-term  data  with  regard  to 
cardiovascular  endpoints  and  endometrial  cancer  in 
these  populations.  Although  randomized,  controlled 
trials have shown no increase in hyperplasia or cancer 
with  tibolone  over  a  mean  duration  of  2  years,  two 
observational studies have reported an increased risk of 
endometrial cancer in tibolone users
56,57. However, it is 
not  known  whether  this  result  is  biased  due  to  pre 
existing endometrial abnormalities or prior use of other 
forms of HRT. 
Figure  1  Algorithm  for  the  use  of  tibolone  in  Asian  menopausal  women.  *,  Tibolone  treatment  is  preferable  to  hormone 
replacement therapy (HRT) for postmenopausal women who report mastalgia, breast tenderness, increasing mammographic density 
and sexual problems. 
{, Contraindications for tibolone should be considered the same as for estrogen–progestogen therapy/estrogen 
therapy (EPT/ET). In addition, tibolone should only be used in women with no history of breast cancer. Tibolone should be used 
with caution in elderly women (i.e. over 60 years) and should not be used in those who have strong risk factors for stroke. OSTA, 
Osteoporosis self-assessment tool for Asians; FRAX, World Health Organization’s fracture risk assessment tool; BP, blood pressure; 
BMD, bone mineral density; DXA, dual-energy X-ray absorptiometry; AEs, adverse events 
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Published data on the possible effects of tibolone in 
diabetes and on stress incontinence in Asian women are 
also lacking, as are large studies of the effect of tibolone 
on breast cancer risk in these populations. It was also 
suggested that the efﬁcacy of lower doses than those 
recommended in the prescribing information might be 
explored in Asian women via controlled studies. 
ALGORITHM  FOR  THE  USE  OF 
TIBOLONE  IN  ASIAN  MENOPAUSAL 
WOMEN 
To provide clear guidance on when tibolone can be used 
and how it ﬁts in with other available treatments for 
menopausal symptoms, the algorithm shown in Figure 1 
was  developed.  Although  symptoms  and  treatment 
modalities particular to Asian postmenopausal women 
are  taken  into  account,  the  algorithm  is  generally 
applicable to women of all ethnicities. 
During the discussions that resulted in this algorithm, 
the expert panel agreed that, on the basis of the clinical 
evidence available, women who might beneﬁt from a 
switch  to  tibolone  from  HRT  included  those  who 
experienced: 
(1)  An  increase  in  breast  pain  despite  HRT  dose 
adjustment; 
(2)  Increased  breast  density  that  resulted  in  an 
unreadable mammogram; 
(3)  Low libido; 
(4)  Mood disorders; and 
(5) Persistent bleeding problems (providing no histo 
pathological reasons for this exist). 
Asian  women  can  be  more  reticent  about  discussing 
sexual  dysfunction  than  Western  women,  despite  the 
fact that it is reported by up to 50% of postmenopausal 
women in some Asian countries
19,27,60. Nevertheless, in 
a multinational survey of 1000 Asian postmenopausal 
women,  71%  regarded  sex  as  an  important  part  of 
marriage
20, and, hence, the inclusion of this item in the 
algorithm  is  intended  to  prompt  the  clinician  to 
overcome  any  reluctance  to  raise  the  subject  with 
postmenopausal patients. As tibolone is more effective 
in improving sexual function than HRT
8,34,44, women 
who experience related problems are likely to beneﬁt 
from it. 
Contraindications for tibolone should be considered 
the  same  as  for  EPT/ET.  As  mentioned  previously, 
tibolone should only be used in women with no history 
of breast cancer. Although there are no data to suggest 
an increased risk of venous thromboembolism to date, 
on the basis of ﬁndings in the LIFT study
16, tibolone 
should be used with caution in elderly women (i.e. over 
60  years)  or  those  who  have  strong  risk  factors  for 
stroke  such  as  hypertension,  smoking,  diabetes  and 
atrial ﬁbrillation. 
CONCLUDING  REMARKS 
Asians are multi-ethnic and differ with regard to dietary 
habits,  attitudes  to  the  menopause  and  menopausal 
symptoms, both amongst themselves and from Western 
women.  This  paper  is  intended  to  address  the  need 
for  clear, up-to-date  recommendations  for  the  use  of 
tibolone,  particularly  in  light  of  these  differences. 
Although data from large clinical trials on the effects 
of  tibolone  in  Asian  women  are  limited,  we  have 
reviewed  data  on  menopausal  symptoms  in  Asian 
women and identiﬁed areas in which the speciﬁc use 
of tibolone might offer particular advantages to them as 
they  pass  the  menopause  transition.  Based  on  a 
thorough review of the most recent clinical trial data 
on tibolone, its known effects have been summarized in 
consensus  statements  that  are  supported  by  levels  of 
evidence,  and  a  treatment  algorithm  is  provided  to 
aid  in  the  selection  of  appropriate  treatment  for  all 
postmenopausal women. 
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